Key result
Nonanthracycline anticancer drugs can cause a wide spectrum of cardiac and cardiovascular adverse effects, ranging from subclinical abnormalities to life-threatening sequelae.
Why the study?
What are the cardiac and cardiovascular toxicities associated with nonanthracycline anticancer drugs?
Population
Patients receiving nonanthracycline anticancer drugs
Design
Review
Authors
Loading...
Alerts clinicians to monitor diverse CV toxicities; leaves optimal risk stratification and mitigation strategies open.
What are the cardiac and cardiovascular toxicities associated with nonanthracycline anticancer drugs?
Knowledge of the diverse cardiovascular toxicities of nonanthracycline anticancer drugs aids clinicians in choosing the optimal and least toxic regimen for individual patients.
Jones et al. (2006) conducted a review in Cancer / Cardiotoxicity. Nonanthracycline anticancer drugs was evaluated. Nonanthracycline anticancer drugs can cause a wide spectrum of cardiac and cardiovascular adverse effects, ranging from subclinical abnormalities to life-threatening sequelae.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: